1. Home
  2. CGON vs VYX Comparison

CGON vs VYX Comparison

Compare CGON & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • VYX
  • Stock Information
  • Founded
  • CGON 2010
  • VYX 1881
  • Country
  • CGON United States
  • VYX United States
  • Employees
  • CGON N/A
  • VYX N/A
  • Industry
  • CGON
  • VYX
  • Sector
  • CGON
  • VYX
  • Exchange
  • CGON NYSE
  • VYX Nasdaq
  • Market Cap
  • CGON 1.3B
  • VYX 1.2B
  • IPO Year
  • CGON 2024
  • VYX N/A
  • Fundamental
  • Price
  • CGON $24.13
  • VYX $10.18
  • Analyst Decision
  • CGON Strong Buy
  • VYX Strong Buy
  • Analyst Count
  • CGON 11
  • VYX 6
  • Target Price
  • CGON $62.90
  • VYX $15.17
  • AVG Volume (30 Days)
  • CGON 2.0M
  • VYX 1.9M
  • Earning Date
  • CGON 05-16-2025
  • VYX 05-08-2025
  • Dividend Yield
  • CGON N/A
  • VYX N/A
  • EPS Growth
  • CGON N/A
  • VYX N/A
  • EPS
  • CGON N/A
  • VYX 6.72
  • Revenue
  • CGON $1,139,000.00
  • VYX $2,733,000,000.00
  • Revenue This Year
  • CGON N/A
  • VYX N/A
  • Revenue Next Year
  • CGON $16,237.24
  • VYX N/A
  • P/E Ratio
  • CGON N/A
  • VYX $1.53
  • Revenue Growth
  • CGON 461.08
  • VYX N/A
  • 52 Week Low
  • CGON $14.80
  • VYX $7.55
  • 52 Week High
  • CGON $40.47
  • VYX $15.34
  • Technical
  • Relative Strength Index (RSI)
  • CGON 51.00
  • VYX 67.18
  • Support Level
  • CGON $21.00
  • VYX $8.55
  • Resistance Level
  • CGON $30.23
  • VYX $9.05
  • Average True Range (ATR)
  • CGON 2.31
  • VYX 0.34
  • MACD
  • CGON 0.16
  • VYX 0.22
  • Stochastic Oscillator
  • CGON 34.09
  • VYX 93.10

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

Share on Social Networks: